Abstract: The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitinization of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
Type:
Application
Filed:
January 30, 2020
Publication date:
July 30, 2020
Applicant:
MONTELINO THERAPEUTICS, LLC
Inventors:
Jenny Desantis, Roy Joseph Vaz, Isaac Kim